Treatment of transformed or infected biological cells

Details Treatment of transformed or infected biological cells Treatment of transformed or infected biological cells

2011-05-10

2011-05-10

Burkhart, Michael (Department: 1633)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

Reexamination Certificate

active

07939266

ABSTRACT:
The present invention relates to a therapeutic or/and diagnostic substance. Furthermore it relates to an expression vector, to a composition comprising the afore-mentioned substance or/and the afore-mentioned expression vector, a method for diagnosing a tumor disease or/and an infectious disease in a living being, as well as to a method for the treatment of a tumor disease or/and of an infection in a living being.

REFERENCES:
patent: 6495664 (2002-12-01), Cubitt
patent: 2005/0112700 (2005-05-01), Perez et al.
patent: 1 207 395 (2002-05-01), None
patent: 1 233 060 (2002-08-01), None
patent: WO 01/07638 (2001-02-01), None
patent: WO 2004/022773 (2004-03-01), None
patent: WO 2004/042404 (2004-05-01), None
patent: WO 2004/068139 (2004-08-01), None
Irish et al. Cell 118:217-228, 2004.
Buggins et al. J. Immunol. 167:6021-6030; 2001.
Cell Signaling Technology Catalog; Phospho-Rb Antibody #2181; p. 1.
“Use of an Oriented Peptide Library to Determine the Optimal Substrates of Protein as Kinases”, Songyang et al., Current Biology, vol. 4, No. 11, 1994, pp. 973-982.
“Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2-phenylaminopyrimidine Class”, Buchdunger et al., Proc. Natl. Acad. Sci., vol. 92, Mar. 1995, pp. 2558-2562.
“Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells”, Druker et al., Nature Medicine, vol. 2, No. 5, May 1996, pp. 561-566.
“A Structural Basis for Substrate Specificities of Protein Ser/Thr Kinases: Primary Sequence Preference of Casein Kinases I and II, NIMA, Phosphorylase Kinase, Calmodulin-Dependent Kinase II, CDK5, and Erkl”, Songyang et al., Molecular and Cellular Biology, vol. 16, No. 11, Nov. 1996, pp. 6486-6493.
“The Structural Basis for Specificity of Substrate and Recruitment Peptides for Cyclin-Dependent Kinases”, Brown et al., Nature Cell Biology, vol. 1, Nov. 1999 pp. 438-443.
“The Hallmarks of Cancer”, Hanahan et al., Cell, vol. 100, Jan. 7, 2000, pp. 57-70.
“Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase”, Schindler et al., Science, vol. 289, Sep. 15, 2000, pp. 1938-1942.
“Modelling the Molecular Circuitry of Cancer”, Hahn et al., Nature Reviews, vol. 2, May 2002, pp. 331-341.
“Rules for Making Human Tumor Cells”, Hahn et al., New England Journal of Medicine, vol. 347, No. 20, Nov. 14, 2002, pp. 1593-1603.
“Recycling the Cell Cycle: Cyclins Revisited”, Murray, Cell, vol. 116, Jan. 23, 2004, pp. 221-234.
“Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice”, Traggiai et al, Science, vol. 304, Apr. 2, 2004, pp. 104-107.
“Cancer Immunotherapy: A Treatment for the Masses”, Blattman et al., Science, vol. 305, Jul. 9, 2004, pp. 200-205.
“Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells”, Irish et al., Cell, vol. 118, Jul. 23, 2004, pp. 217-228.
“Caged Phosphopeptides Reveal a Temporal Role for 14-3-3 in G1 Arrest and S-phase Checkpoint Function”, Nguyen et al., Nature Biotechnology, vol. 22, No. 8, Aug. 2004, pp. 993-1000.
“Cytostatic Anticancer Drug Development”, Gardner et al., Journal of Experimental Therapeutics and Oncology, vol. 4, 2004, pp. 9-18.
“A Genetically Encoded Fluorescent Reporter of Histone Phosphorylation in Living Cells”, Lin et al., Angew. Chem. Int. Ed. 43, 2004, pp. 2940-2943.
“The Structural Basis for Specificity of Substrate and Recruitment Peptides for Cyclin-Dependent Kinases”, Brown et al., Nature Cell Biology, vol. 1, No. 7, Nov. 1999, pp. 438-443.
“Site-Specific Phosphorylation of Retinoblastoma Protein Due to Different Cyclin-Dependent Kinase Activities in Childhood Acute Lymphoblastic Leukemia (ALL)”, Hirt et al., W.B. Saunders Company, vol. 98, No. 11, Part 2, Nov. 16, 2001, 1 page.
International Search Report in PCT/EP2005/008976 dated Jan. 12, 2006.
Website http://www.physiomics-plc.com/Q3.htm.
“Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells,” Salih et al., American Association of Immunologists, Copyright 2000, pp. 2903-2910.
“Transcriptional Regulation and Function During the Human Cell Cycle,” Cho et al., Nature Genetics, vol. 27, Jan. 2001, pp. 48-54.
“Cancer Genes and the Pathways They Control,” Vogelstein et al., Nature Medicine, vol. 10, No. 8, Aug. 2004, pp. 789-799.
“Multiple Ras Effector Pathways Contribute to G1, Cell Cycle Progression,” Gille et al., The Journal of Biological Chemistry, vol. 274, No. 31, Jul. 30, 1999, pp. 22033-22040.
“Growth-Factor-Dependent Mitogenesis Requires Two Distinct Phases of Signalling,” Jones et al., Nature Cell Biology, vol. 3, Feb. 2001. pp. 165-172 (with supplementary information, pp. 1-3).
“Regulation of Ras Signaling by the Cell Cycle,” Stacey et al., Current Opinion in Genetics & Development, vol. 12, pp. 44-46, 2002.
Website http://www.infobiogen.fr/services/chromcancer, Jul. 2006.
Website http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD—searc&DB=omim, Aug. 2006.
Website http://www.nature.com/horizon/chemicalspace/highlights/s5-specl.html, Aug. 2006.
Website http://invitrogen.com, Jul. 2006.

Affiliated with

Also associated with

Rating

Treatment of transformed or infected biological cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of transformed or infected biological cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of transformed or infected biological cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2675511